Rallybio Corporation (RLYB)
| Market Cap | 89.67M +242.8% |
| Revenue (ttm) | 646,000 -15.1% |
| Net Income | 45.55M |
| EPS | 7.99 |
| Shares Out | 5.31M |
| PE Ratio | 2.11 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,443 |
| Open | 16.81 |
| Previous Close | 16.80 |
| Day's Range | 16.64 - 17.03 |
| 52-Week Range | 3.67 - 17.57 |
| Beta | -0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ... [Read more]
Financial Performance
In 2025, Rallybio's revenue was $858,000, an increase of 34.91% compared to the previous year's $636,000. Losses were -$8.98 million, -84.46% less than in 2024.
Financial StatementsNews
Rallybio Quarterly report: Q2 2026
Rallybio has published its Q2 2026 quarterly earnings report on August 6, 2026.
Rallybio to acquire Avenzo Therapeutics through merger transaction
Rallybio (RLYB) Corporation and Avenzo Therapeutics entered into a definitive agreement pursuant to which Rallybio will acquire Avenzo through a merger transaction. Upon completion of the Merger, the ...
Rallybio Transcript: M&A announcement
The merger will combine oncology pipelines and expertise, supported by a $215M capital raise, to advance four clinical-stage programs and extend the cash runway into late 2028. The combined company aims to achieve multiple clinical milestones and expand its market presence.
Rallybio Press release: M&A announcement
Rallybio issued a press release on June 1, 2026, disclosing material business information to investors.
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
NEW HAVEN, Conn. & SAN DIEGO, Calif.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next...
Rallybio Quarterly report: Q1 2026
Rallybio has published its Q1 2026 quarterly earnings report on May 13, 2026.
Rallybio Annual report: Q4 2025
Rallybio has published its Q4 2025 annual report on March 16, 2026.
Rallybio, Candid Therapeutics announce merger agreement
Rallybio (RLYB) and Candid Therapeutics announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction. Upon completion of the...
Rallybio Transcript: M&A announcement
The merger creates a leading TCE therapeutics company for autoimmune diseases, combining robust pipelines and over $500 million in capital to advance multiple candidates into late-stage clinical trials. The combined entity aims for global leadership and accelerated development timelines.
Rallybio Press release: M&A announcement
Rallybio issued a press release on March 2, 2026, disclosing material business information to investors.
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a lead...
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Corp trading halted, news pending
19:50 EST Rallybio (RLYB) Corp trading halted, news pending
Rallybio announces reverse 1-for-8 stock split
Rallybio (RLYB) Corporation will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restate...
Rallybio Announces Reverse Stock Split of Common Stock
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an ...
Rallybio Transcript: EGM 2026
Stockholders approved an amendment for a reverse stock split at a ratio between 1:5 and 1:20, with a quorum of 82.81% present. Final results will be disclosed in a Form 8-K within four business days.
Rallybio Proxy statement: Proxy Filing
Rallybio filed a proxy statement on January 2, 2026, providing details for shareholder voting and corporate governance matters.
Rallybio Proxy statement: Proxy Filing
Rallybio filed a proxy statement on December 23, 2025, providing details for shareholder voting and corporate governance matters.
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio Quarterly report: Q3 2025
Rallybio has published its Q3 2025 quarterly earnings report on November 6, 2025.
Rallybio Earnings release: Q3 2025
Rallybio released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
Rallybio completes dosing of first cohort in RLYB116 study
Rallybio (RLYB) announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s once-weekly, small volume, su...
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals
Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was triggered by the initiation of additional preclinical ...
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...